Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: A prospective, multicenter, double-blind, randomized trial

Journal of Urology

Volumn 192, Issue 6, 2014, Pages 1743-1749

  Chuang, Yao Chi ^a   Kaufmann, Jonathan H ^c   Chancellor, David D ^c   Chancellor, Michael B ^c,d   Kuo, Hann Chorng ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c Lipella Pharmaceuticals Inc   (United States)

^d OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

onabotulinumtoxin Aliposomes; overactive; urinary bladder

Indexed keywords

BOTULINUM TOXIN A; LIPOSOME; PLACEBO; SODIUM CHLORIDE; ACETYLCHOLINE RELEASE INHIBITOR;

ADULT; ARTICLE; BLADDER IRRIGATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LIPOSOMAL DELIVERY; MAJOR CLINICAL STUDY; MALE; MICTURITION; MIDDLE AGED; MULTICENTER STUDY; OVERACTIVE BLADDER; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URGE INCONTINENCE; URINARY URGENCY; URINE RETENTION; AGED; CLINICAL TRIAL; INTRAVESICAL DRUG ADMINISTRATION; REMISSION; URINARY BLADDER, OVERACTIVE;

ACETYLCHOLINE RELEASE INHIBITORS; ADMINISTRATION, INTRAVESICAL; AGED; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; URINARY BLADDER, OVERACTIVE;

EID: 84914148288     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.07.008     Document Type: Article

References (23)

1. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology of lower urinary tract function: report from the standardization sub-committee of the international continence society Neurourol Urodyn 21 2002 167
2. D.E. Irwin, Z.S. Kopp, and B. Agatep Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction BJU Int 108 2011 1132
3. H.J. Yu, C.Y. Liu, and K.L. Lee Overactive bladder syndrome among community-dwelling adults in Taiwan: prevalence, correlates, perception, and treatment seeking Urol Int 77 2006 327
4. E.A. Gormley, D.J. Lightner, and K.L. Burgio Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline J Urol 188 2012 2455
5. N. Buser, S. Ivic, and T.M. Kessler Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses Eur Urol 62 2012 1040
6. M. Dong, F. Yeh, and W.H. Tepp SV2 is the protein receptor for botulinum neurotoxin A Science 312 2006 592
7. Y.C. Chuang, H.C. Kuo, and M.B. Chancellor Botulinum toxin for the lower urinary tract BJU Int 105 2010 1046
8. K.R. Aoki Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A Neurotoxicology 26 2005 785
9. A. Giannantoni, S.M. Di Stasi, and V. Nardicchi Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity J Urol 175 2006 2341
10. Y.C. Chuang, N. Yoshimura, and C.C. Huang Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats J Urol 172 2004 1529
11. 3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity J Urol 174 2005 977
12. H.C. Kuo Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents Urology 63 2004 868
13. R. Dmochowski, C. Chapple, and V.W. Nitti Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial J Urol 184 2010 2416
14. Y.C. Chuang, P. Tyagi, and C.C. Huang Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes J Urol 182 2009 786
15. E. Whitley, and J. Ball Statistics review 6: nonparametric methods Critical Care 6 2002 509
16. S.M. Finney, K.E. Andersson, and J.I. Gillespie Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98 2006 503
17. A. Giannantoni, S.M. Di Stasi, and M.B. Chancellor New frontiers in intravesical therapies and drug delivery Eur Urol 50 2006 1183
18. L.A. Birder More than just a barrier: urothelium as a drug target for urinary bladder pain Am J Physiol Renal Physiol 289 2005 F489
19. L.A. Birder, and W.C. de Groat Mechanisms of disease: involvement of the urothelium in bladder dysfunction Nat Clin Pract Urol 4 2007 46
20. C.J. Tzan, J.R. Berg, and S.A. Lewis Mammalian urinary bladder permeability is altered by cationic proteins: modulation by divalent cations Am J Physiol 267 1994 C1013
21. C.C. Hsu, Y.C. Chuang, and M.B. Chancellor Intravesical drug delivery for dysfunctional bladder Int J Urol 20 2013 552
22. Y.C. Chuang, W.C. Lee, and P.H. Chiang Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome J Urol 182 2009 1393
23. H.C. Kuo, H.T. Liu, and Y.C. Chuang Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: a single-center study Eur Urol 65 2014 1117